AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00499408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy
Description: Patients will receive oral supplementation of soy (160 mg per day soy isoflavones).
Study NCT00539929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201 0.005%
Study NCT00539929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201 0.01%
Study NCT00539929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201 0.03%
Study NCT00539929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00494715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril
Description: Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
Study NCT00494715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
Study NCT00494715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril/Valsartan
Description: Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
Study NCT01902459 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EVARREST™ Fibrin Sealant Patch
Description: EVARREST™ Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
Study NCT01902459 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care will be manual compression (MC) with or without a topical absorbable hemostat (TAH) or any other adjunctive hemostasis technique that is deemed by the surgeon to be his/her standard of care.
Study NCT03216759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Description: After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning then patients received ischemic preconditioning.
Study NCT03216759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: At the beginning of anesthesia induction, 3 ug/kg/h of dexmedetomidine was infused and adjusted to 0.3 ug/kg/h after 10 min of infusion until 30 minutes before the end of the procedure.
Study NCT03216759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia
Description: Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap.The first volume of morphine 2mg + 0.2% ropivacaine + 0.9% saline 6ml, maintenance dose of morphine 18mg + 0.1% ropivacaine + 0.9% saline total 150ml. PCEA work with a continuous background dose of 2 ml/h with a single dose of 2ml/time, load 2ml, locking time 15min.
Study NCT00084981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT00084981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid
Description: Given PO
Study NCT00084981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00084981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00694213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCL-IPM1
Description: IM, 0.5 mg/mL, 2 injections, 0 and 21 days
Study NCT00694213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCL-IPM1
Description: IM, 1 mg/mL, 2 injections, 0 and 21 days
Study NCT00694213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCL-IPT1
Description: IM, 1 mg/mL, 2 injections, 0 and 21 days
Study NCT00694213 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PBS
Description: IM, 1 mL, 2 injections, 0 and 21 days
Study NCT01830582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced MR Imaging
Study NCT02746991 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Placebo
Study NCT02746991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAI Insert
Description: Fluocinolone Acetonide
Study NCT00245726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Cycle
Description: Subjects will use electrical stimulation of the leg muscles to pedal a cycle for 1 hour / 3x week
Study NCT00245726 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ES therapy
Description: Subjects will electrically stimulate the leg muscles for 1 hour/ 3x week
Study NCT00245726 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive (Motor Assist) Cycle
Description: Subjects will use a cycle that moves the legs for 1 hour/3x per week
Study NCT00890604 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen
Description: It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.
Study NCT00890604 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetominophen
Description: It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.
Study NCT03709212 — intervention group
Intervention type: OTHER
Intervention: interviews
Description: 20 participants will undergo individual semi-structured interviews, 60 will undergo one of 6 focus groups comprising of 10 participants of the same gender and ethnicity.
Study NCT02544256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Description: Mild hypothermia during surgical clipping of brain aneurysm will be reached by cooling to body temperature 33,8° C - 34,8° and this temperature maintained up to the end of microcirculation measurement after aneurysm clipping.
Study NCT02892929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: The approach combines the principles of patient-centered care with strategies to motivate the change.~Since the first appointment, Motivational Interviewing techniques will be used aiming to work the ambivalence that is to seek treatment and modify the unhealthy behavior. From the second encounter until the appointment of 120 days, the participants will be subjected to individual encounters in which the MI approach will be applied focusing on behavior change.
Study NCT02892929 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prescriptive Consultation
Description: Prescriptive consultation is the Methodology usual consultation, in which the patient has little room to express themselves and the health professional who determines what and how the patient will hold the care of your health.
Study NCT03378752 — intervention group
Intervention type: PROCEDURE
Intervention: HFJV
Description: On High frequency jet ventilation, Every 15 minutes, after induction of general anaesthesia, a computed tomography of the lower part of the lungs are taken (10 cm volume, with the top of the right diaphragm as the lower border)
Study NCT02971098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced activity
Description: Participants will reduced their physical activity level to approximately 2000 steps or 75% of their normal activity levels.
Study NCT04585880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Collaborative Care Clinic
Description: The vCCC will operate under a collaborative care agreement with the Primary Care Physicians as an extension (and not a replacement) of their care. Trained clinical pharmacists will monitor blood pressure and prescribe and adjust medications under the license of, and in communication with, the patient's Primary Care Physician. As part of the Primary Care Physician's team and per Primary Care Physician's directions, the pharmacists may coordinate blood pressure management with other clinicians such as cardiologists or nephrologists co-managing patients blood pressure.
Study NCT03449446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: 18 mg tablet administered orally once daily without regard to food
Study NCT00795912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
Study NCT03449446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIR
Description: 20 mg tablet administered orally once daily without regard to food
Study NCT02038660 — intervention group
Intervention type: DEVICE
Intervention: Balloon angioplasty
Study NCT03449446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CILO
Description: 30 mg tablet administered orally once daily without regard to food
Study NCT03449446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match FIR
Description: Tablet administered orally once daily without regard to food
Study NCT03449446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match CILO
Description: Tablet administered orally once daily without regard to food
Study NCT03449446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match SEL
Description: Tablet administered orally once daily without regard to food
Study NCT03032679 — intervention group
Intervention type: OTHER
Intervention: Non interventional study
Description: No intervention
Study NCT00142623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored DVDs
Description: Five DVDs aimed at reducing exposure to ETS
Study NCT00579995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral N-Acetylcysteine
Description: 600 milligrams (mg)
Study NCT03055988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: Fixed Dose Combination
Study NCT03055988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fixed Dose Combination
Study NCT03055988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Fixed Dose Combination
Study NCT00082238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable isotopes
Description: Stable isotopes were used to quantify gluconeogenesis GNG, hepatic glucose production (HGP), and protein breakdown.
Study NCT00082238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stable isotopes
Description: Stable isotopes were used to quantify gluconeogenesis GNG, hepatic glucose production (HGP), and protein breakdown.
Study NCT05310006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise sessions were performed in the morning (07:00 am-12:00 am) under the supervision of at least two fitness instructors in the rehabilitation unit of the nursing home.HSRE and TRE were designed according to the peculiarities of each type of resistance exercise (Chodzko-Zajko et al., 2009). During TRE, participants performed four sets of 8-10 repetitions at 70-75% of the maximal strength. The concentric and eccentric phases were carried out for 2 s. For HSRE, exercises were performed eight times (sets) with 4-5 repetitions at 70-75% of the maximal strength. The concentric phase was performed as fast as possible, and the eccentric phase was carried out for 2 s. Bilateral calf raise was performed using the same load as unilateral knee extension.
Study NCT00579995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: 3 milliliters per kilogram per hour (mL/kg/hr) for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure
Study NCT02349867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT02349867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO
Study NCT02349867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT02349867 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D CRT
Study NCT02349867 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT02349867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RosetteSep
Description: Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by negative-selection techniques (RosetteSep). Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
Study NCT02349867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DEPfff
Description: Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by with the ApoStream dielectrophoretic field-flow fractionation (DEPfff) enrichment device. Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
Study NCT02381184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
Study NCT02381184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic ovarian drilling (LOD)
Description: Laparoscopy was performed under general anesthesia, using three-puncture technique
Study NCT02963233 — intervention group
Intervention type: PROCEDURE
Intervention: Closed reduction and percutaneous pinning and immobilization
Study NCT02963233 — intervention group
Intervention type: PROCEDURE
Intervention: Non-operative reduction and immobilization
Study NCT00862472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DuoTrav APS
Description: DuoTrav APS QD AM
Study NCT00862472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DuoTrav
Description: DuoTrav QD AM
Study NCT05113667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pharmacist-led Appropriate Acid Suppression Therapy Stewardship Program
Description: Clinical pharmacist provided medication reconciliation and medication review during the hospital stay.
Study NCT04591249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Participants will 1) receive Fitbit, 2) be enrolled in a secure electronic platform to access Fitbit data, 3) receive 8-week remote counseling by a physical therapist that will include motivational interviewing and creating SMART goals (1 session per week) through a web-based teleconference platform, and 4) receive usual postoperative care directed by their surgeon. The first session will be 45 minutes and sessions 2-8 will be 30 minutes each. During the sessions, participant's confidence in meeting daily step goals will be assessed using a 0-10 scale. If self-reported confidence to meet their goal is \<8, the physical therapist will help participants modify their goal using techniques such as problem-solving, positive statements and affirmations. Progression will be made only if daily steps goals are met for at least 4 out of 7 days a week. If this weekly step goal is not met, a physical therapist will help the participant identify solutions for realistic progression.
Study NCT04591249 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants will receive postoperative care as determined by their treating surgeon. This includes lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
Study NCT04591249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants will receive postoperative care as determined by their treating surgeon. This includes lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
Study NCT03047291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
Study NCT03047291 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
Study NCT02578342 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency
Study NCT02558400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG324 Ophthalmic Solution 0.02%/0.005%
Description: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)
Study NCT02558400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netarsudil (AR-13324) Ophthalmic Solution 0.02%
Description: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)
Study NCT02558400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost Ophthalmic Solution 0.005%
Description: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)
Study NCT00973882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles
Study NCT00973882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles
Study NCT02631733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV
Study NCT02631733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Sucrosofate
Description: Given IV
Study NCT02631733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03715218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mothers Touch Program
Description: Mothers Touch Program with bed rest, Relaxation program to reduce stress, massage for mother and infant, gently physical exercise and special dietary program each week.
Study NCT03715218 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Program
Description: Usual care group had advice, support and educational program delivered by midwife, or physicians.
Study NCT02398955 — intervention group
Intervention type: DEVICE
Intervention: percutaneous coronary intervention
Description: percutaneous coronary angioplasty with implantation of at least one Biomime stent
Study NCT01995214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthesia maintenance with propofol+remifentanil guided by Narcotrend index monitoring.
Study NCT01995214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia maintenance with sevoflurane+remifentanil guided by Narcrotrend index monitoring.
Study NCT02378701 — intervention group
Intervention type: BEHAVIORAL
Intervention: QUALMS-1 Questionnaire
Description: Participants complete the QUALMS-1 during first treatment visit, and after 4th cycle of treatment or when treatment stops.
Study NCT02378701 — intervention group
Intervention type: BEHAVIORAL
Intervention: FACT-An Questionnaire
Description: Participants complete the FACT-An during first treatment visit, and after 4th cycle of treatment or when treatment stops.